MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2018 International Congress

    Development of a biomarker for Parkinson’s disease by measuring alpha-synuclein oligomers in cerebrospinal fluid with ultrasonication-induced amyloid fibril formation

    K. Kakuda, K. Ikenaka, K. Araki, Y. Kajiyama, M. So, H. Hayakawa, T. Omichi, K. Baba, K. Konaka, T. Tokuda, Y. Goto, H. Mochizuki (Suita, Japan)

    Objective: To establish a new technique quantifying misfolded alpha-synuclein (αSyn) oligomers in the CSF and to investigate their clinical - pathological significances in Parkinson’s disease…
  • 2018 International Congress

    Exercise to improve upper limb function in people with Parkinson’s disease: A systematic review

    E. Proud, J. Blennerhassett, J. Tan, K. Miller, M. Morris, J. McGinley (Parkville, Australia)

    Objective: To review the effectiveness and describe the exercise parameters of interventions targeting upper limb (UL) function in people with PD. Background: Reduced fine hand…
  • 2018 International Congress

    The effects of treadmill training augmented by virtual reality on postural control and freezing of gait in Parkinson’s disease

    E. Bekkers, A. Mirelman, S. Del Din, L. Avanzino, F. Nieuwhof, J. Hausdorff, A. Nieuwboer (Leuven, Belgium)

    Objective: To investigate whether treadmill training with virtual reality is beneficial both for Parkinson’s disease patients with and without freezing of gait (FOG) to address…
  • 2018 International Congress

    Efficacy of CVT-301 (levodopa inhalation powder) for treatment of OFF periods in Parkinson’s disease

    R. Pahwa, I. Abeynayake, M. Klingler, A. Sedkov, C. Kenney, C. Oh (Overland Park, KS, USA)

    Objective: Post-hoc analysis of subjects with Parkinson’s disease (PD) achieving > 30% reduction in UPDRS motor score (UPDRSIII) from pre- to post-dose over the first…
  • 2018 International Congress

    Activities of Daily Living and Quality of Life in Patients with Advanced Parkinson’s Disease Who Are Treated with or Planning to Use Device-Aided Treatments

    A. Fasano, K. Seppi, V. Fung, Z. Pirtosek, J.C. Parra, L. Bergmann, O. Sanchez-Soliño, B. Elibol, K. Onuk (Toronto, ON, Canada)

    Objective: To correlate activities of daily living (ADL) and quality of life (QoL) in advanced Parkinson’s disease (APD) patients with ongoing or planned device-aided treatment…
  • 2018 International Congress

    Bio-Electro Stimulation Therapy for the Treatment of Motor and Non-Motor Symptoms in Parkinson’s Disease

    T. Tsao, C. Fontana, A. Waite (Boston, MA, USA)

    Objective: Design an experiment to assess tremor severity comparable to the current clinical standard using Shimmer3 sensors. Investigate collected data to see if BEST intervention…
  • 2018 International Congress

    Final MDS-UPDRS, Part IV Results of the EASE LID 2 Study: Long Term, Open-Label Study of ADS-5102 for Dyskinesia in Parkinson’s disease (PD) patients

    R. Hauser, R. Pahwa, C. Tanner, W. Oertel, R. Johnson, L. Felt, MJ. Stempien, R. Patni (Tampa, FL, USA)

    Objective: An objective of this study was to evaluate the long-term duration of ADS-5102 effect on dyskinesia as assessed by the Unified Parkinson’s Disease Rating…
  • 2018 International Congress

    Intranasal delivery of insulin for the restoration of memory signaling in Alzheimer disease

    S. Bhargava, V. Bhargava, A. Jain (Kanpur, India)

    Objective: Objective of this study is to develop delivery-system to overcome BBB by employing novel, non-invasive approach via nasal route. Background: Alzheimer's disease(AD), a form…
  • 2018 International Congress

    Effects of Botulinum Toxin treatment for sialorrhea in patients with cerebral palsy

    J. Francês Brito, M. Akkari, A. Pinheiro Alves, A. Barbosa de Sousa Junior, B. De Oliveira, O. Vieira Kishi, Jose Roberto Bentes Capeloni (Belem, Brazil)

    Objective: To evaluate the benefits of treatment of drooling with Botulinum Toxin Type A (AbobotulinumtoxinA) in patients with cerebral palsy. Background: Patients with cerebral palsy…
  • 2018 International Congress

    A Randomized Trial of Deferiprone for Pantothenate Kinase-Associated Neurodegeneration

    T. Klopstock, F. Tricta, L. Neumayr, I. Karin, G. Zorzi, C. Fradette, T. Kmieć, B. Buechner, H. Steele, R. Horvath, P. Chinnery, A. Basu, C. Küpper, C. Neuhofer, P. Dušek, F. Zhao, F. Zibordi, N. Nardocci, C. Aguilar, S. Hayflick, M. Spino, A. Blamire, P. Hogarth, E. Vichinsky (Munich, Germany)

    Objective: To investigate whether treatment with the iron-chelating drug deferiprone (DFP) has benefit in patients with pantothenate kinase-associated neurodegeneration (PKAN), the most common form of…
  • « Previous Page
  • 1
  • …
  • 24
  • 25
  • 26
  • 27
  • 28
  • …
  • 177
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
        • Help & Support
        • About Us
        • Cookies & Privacy
        • Wiley Job Network
        • Terms & Conditions
        • Advertisers & Agents
        Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
        Wiley